What It Is

Retatrutide + Cagrilintide is a next-generation multi-pathway metabolic research blend. Retatrutide functions as a triple agonist targeting GIP, GLP-1, and glucagon receptors, while Cagrilintide is a long-acting synthetic amylin receptor agonist. This combination pairs triple incretin/glucagon activation with non-incretin amylin pathway signaling.

What It Is Commonly Used For

• Multi-Pathway Appetite & Satiety Signaling: Studied for dual central nervous system satiety stimulation, combining incretin receptor pathways with brainstem amylin receptor activation to slow gastric motility.

• Profound Adipose & Weight Reduction: Evaluated in advanced metabolic models for accelerating fat oxidation via glucagon signaling while significantly reducing overall energy intake.

• Synergistic Metabolic & Glycemic Control: Researched for its ability to regulate postprandial blood glucose, suppress excess glucagon release, and enhance metabolic flexibility.

General Purpose

To provide a quadruple-target receptor blend (GIP/GLP-1/Glucagon + Amylin) for investigating advanced weight management, satiety signaling pathways, and multi-receptor metabolic synergy in laboratory research.

Specifications